Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07485907
Starting soon Observational

National Observatory of Children Hospitalized With Bronchiolitis

NCT07485907 · tracked via the Priya Life Science France tracker
Sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Phase
Observational
Started
2026-03-15
Last updated
2026-03-20

Condition(s) studied

Bronchiolitis

Study summary

OVNI3 is multicenter, non-interventional study based on the analysis of retrospective patient data extracted from medical records and collected as part of routine clinical care following hospitalization for bronchiolitis

Eligibility

Sex
ALL
Min age
1 Day
Max age
12 Months
Healthy volunteers
No
Inclusion Criteria: * Children under 12 months * Treated at one of the 12 study sites * From October 15, 2025 to February 15, 2026 * For acute bronchiolitis defined according to current national and international recommendations * Hospitalized and * RSV testing * Known nirsevimab immunization status for the ongoing 2025/2026 season Exclusion Criteria: * Refusal to participate by the legal representative * Maternal immunization with abrysvo after September 1st 2025

Primary outcome measure(s)

  • Evaluate the nirsevimab effectiveness for RSV Bronchiolitis hospitalized vs Non-RSV Bronchiolitis in 2025/2026. — 6 months
    This outcome evaluates the effectiveness of nirsevimab in preventing hospitalizations for RSV bronchiolitis among infants under 12 months of age during the 2025/2026 season. Effectiveness is assessed by comparing the number of hospitalizations for RSV bronchiolitis in infants who received nirsevimab versus those who did not.

Trial sites (1)

FacilityCityRegionStatus
ACTIV Créteil France

More Association Clinique Thérapeutique Infantile du val de Marne trials in France

Bacteriological Evaluation of Children With Otorrhea Recruiting
Pediatric and Ambulatory Research in Infectious Diseases Recruiting
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns Recruiting
CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit Recruiting
RSV Burden in Outpatient and Hospital Settings Recruiting

Other trials for the same condition

PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants Starting soon
Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants Recruiting
Comparison of Two Methods of Immunoprophylaxis Against RSV in Term Newborns Active, not recruiting
Pediatric and Ambulatory Research in Infectious Diseases Recruiting
Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07485907 on ClinicalTrials.gov ↗ ← All trials in France